- Volume is elevated versus the 13-week average, confirming attention.
NATCAPSUQ
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Natural Capsules Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
155.0 INR
8.2%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -0.7% below the Trend Line and sits at 11.7% of its 52-week range. The latest completed week returned 8.2%, after a 7.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
35
out of 100
Latest Close
155.0 INR
7 Aug 2026
1W Return
8.2%
latest completed week
4W Return
7.0%
short-term follow-through
12W Return
1.9%
quarterly tape
Trend Breadth
11.5%
6 of 52 weeks active
Volume Ratio
6.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
8.2%
Latest completed week; four-week move 7.0%.
Indicator stack
6/39
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 37.93%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
9 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -0.7% below the Trend Line and sits at 11.7% of its 52-week range. The latest completed week returned 8.2%, after a 7.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 6.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0412-week average 0.06
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.04Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 7.0% over four weeks, 1.9% over 12 weeks, and -26.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.09Latest activity-pressure read.
Pressure change-121.8%Four-week change in activity pressure.
Leadership-11.86Latest relative-leadership reading.
RS change36.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 85%
Model confidence 79%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength50/100Blend of value, momentum, and quality. Underlying universe rank 51; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum51/100Medium-term price momentum. Underlying universe rank 50; rank 1 is best.
Growth49/100Revenue and earnings growth. Underlying universe rank 52; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.9x Market value relative to trailing revenue.
- EV / EBITDA
- 1956.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 45.3% Gross profit retained from each unit of revenue.
- Operating margin
- -10.0% Operating profit retained from revenue.
- Free-cash-flow margin
- -0.3% Free cash flow generated from revenue.
- Return on invested capital
- -4.2% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 11.5% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.0% Net share repurchases relative to market value.
- Shareholder yield
- -0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 670.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 9 relevant articles.
0 positive · 9 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-47.6%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher9 of 2617 weeks finished lower.
Best week+9.8%Week of 8 May.
Worst week-10.3%Week of 15 May.
Latest week+8.2%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains3
Flat weeks0
Modest losses14
Sharp losses3
Recent vol5.0%13-week weekly-return volatility.
Base vol6.8%52-week weekly-return volatility.
Up/down split18/34Count of positive and negative weeks in the 52-week window.
Average skew6.6% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank22 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape28/100
Trend, activity pressure, participation, and risk combine to a 28/100 tape read.
Indicator analysis25/100Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.
Activity pressure 0.04; No reversal markers Next-Week ExpectancyNegative 37.93%Next-week expectancy is negative with a 37.93% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Tiny Titans rank 70; Buyback Yield rank 73 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 9 relevant articles.
Natural Capsules stake in Natural Biogenex diluted by 2.18% due to rights issue opt-out Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 155.0 INR | 8.2% | 156.2 INR | 189.8 INR | -0.09 | -11.86 | 326.2K | Off |
| 31 Jul 2026 | 143.3 INR | -3.7% | 157.4 INR | 190.3 INR | -0.21 | -18.44 | 30.7K | Off |
| 24 Jul 2026 | 148.9 INR | 4.4% | 159.2 INR | 190.9 INR | -0.02 | -13.72 | 126.7K | Off |
| 17 Jul 2026 | 142.6 INR | -1.7% | 160.1 INR | 191.5 INR | 0.14 | -19.83 | 17.2K | Off |
| 10 Jul 2026 | 145.0 INR | -4.9% | 161.1 INR | 192.1 INR | 0.40 | -18.70 | 23.0K | Off |
| 3 Jul 2026 | 152.4 INR | -2.9% | 162.6 INR | 192.8 INR | 0.56 | -15.34 | 4.0K | Off |
| 26 Jun 2026 | 157.1 INR | -2.5% | 163.8 INR | 193.3 INR | 0.62 | -12.52 | 0 | Off |
| 19 Jun 2026 | 161.1 INR | 3.3% | 164.8 INR | 193.8 INR | 0.67 | -10.65 | 11.8K | Off |
| 12 Jun 2026 | 155.9 INR | -1.0% | 165.6 INR | 194.3 INR | 0.58 | -12.47 | 2.4K | Off |
| 5 Jun 2026 | 157.5 INR | -3.1% | 167.2 INR | 194.9 INR | 0.56 | -11.25 | 2.9K | Off |
| 29 May 2026 | 162.6 INR | 7.5% | 168.5 INR | 195.4 INR | 0.59 | -9.72 | 54.4K | Off |
| 22 May 2026 | 151.3 INR | -0.6% | 170.0 INR | 195.9 INR | 0.51 | -17.02 | 15.0K | Off |
| 15 May 2026 | 152.2 INR | -10.3% | 172.4 INR | 196.6 INR | 0.53 | -16.61 | 15.2K | Off |
| 8 May 2026 | 169.6 INR | 9.8% | 174.6 INR | 197.3 INR | 0.47 | -9.43 | 21.7K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.